Treats HIV-1 infection. ANDA 78119, held by Cipla. Abacavir Sulfate.
As of Nov 16, 2026, ANDA 78119 (Abacavir Sulfate), held by Cipla, was first approved by FDA on Nov 21, 2017, with 2 approved supplements and 0 published complete response letters.
Abacavir tablet, a nucleoside analogue human immunodeficiency virus (HIV-1) reverse transcriptase inhibitor, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Abacavir tablets USP 300 mg, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (HIV-1) infection.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 21, 2017 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Abacavir SulfateEQ 300MG BASE · tablet;oral | Abacavir Sulfate | Rx |
| Mar 28, 2024 | Supplement 29Labeling · Standard review | Approved | None posted |
| Dec 12, 2019 | Supplement 25Labeling · Standard review | Approved | None posted |
| Nov 21, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters